Trial Profile

An real-world, observational study of Endari in in preventing acute complications from sickle cell disease (SCD) and hemolysis in pediatric and adult patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2023 Results (n=6) assessing renal function evolution of SCD patients treated with pharmaceutical-grade L-glutamine in pediatricand adult patients with SCD at follow-up time points of 12 and 30 months after initiation of treatment presented at the 28th Congress of the European Haematology Association
13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
13 Apr 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com